Jefferson, Tom
Tom Jefferson investigador
Tom Jefferson
VIAF ID: 85607982 (Personal)
Permalink: http://viaf.org/viaf/85607982
Preferred Forms
-
-
-
- 100 1 _ ‡a Jefferson, Tom
- 100 1 0 ‡a Jefferson, Tom
-
- 100 1 _ ‡a Jefferson, Tom
-
-
- 100 1 _ ‡a Jefferson, Tom
- 100 0 _ ‡a Tom Jefferson
- 100 0 _ ‡a Tom Jefferson ‡c investigador
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
1st International Symposium on the Evaluation of Safety of Human Vaccines. 22-23 May 2002, Istituto Superiore di Sanitá, Rome, Italy. | |
"Adaptive pathways" to drug authorisation: adapting to industry? | |
Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology | |
Amantadine and rimantadine for influenza A in adults | |
As fate would have it | |
Authors' reply to Dunning | |
Balancing benefits and harms in health care: Observational data on harm are already included in systematic reviews | |
Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications | |
Bioterrorism and compulsory vaccination | |
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). | |
The Brighton Collaboration-enhancing vaccine safety | |
Challenges of independent assessment of potential harms of HPV vaccines | |
Change from oral poliovirus vaccine to inactivated poliovirus vaccine | |
The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias | |
Contradictory findings on efficacy of neuraminidase inhibitors not cited | |
Economic analysis of influenza vaccination and treatment | |
Editorial peer review for improving the quality of reports of biomedical studies | |
Elementary economic evaluation in health care, 1996: | |
Ensuring safe and effective drugs: who can do what it takes? | |
Erfolg im Peer Review : wissenschaftliche Begutachtungen durchführen und überstehen | |
The evidence base for new drugs. | |
The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer | |
Get peered! | |
How to survive peer review | |
Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency | |
The imperative to share clinical study reports: recommendations from the Tamiflu experience | |
Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination | |
Increasing value and reducing waste: addressing inaccessible research | |
Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. | |
[Influenza vaccination for healthcare workers who work with the elderly] | |
Influenza vaccination: policy versus evidence | |
Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011. | |
Interventions to increase influenza vaccination rates of those 60 years and older in the community and in institutions | |
Is the timing of recommended childhood vaccines evidence based? | |
Multisystem failure: the story of anti-influenza drugs | |
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. | |
Neuropsychiatric adverse events and oseltamivir for prophylaxis. | |
Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency | |
Peer review in health sciences | |
Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review | |
Polysaccharide pneumococcal vaccines | |
Possible harms of oseltamivir--a call for urgent action | |
Refining the E in EBM | |
Reply to Letter to the Editor | |
Restoring biomedical literature with RIAT | |
Restoring invisible and abandoned trials: a call for people to publish the findings | |
Rethinking credible evidence synthesis | |
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports | |
Safety and efficacy of inactivated influenza vaccines in children. | |
Selective quotation of evidence in vaccines research | |
Shinario de manabu iryō keizaigaku nyūmon | |
The Spanish influenza pandemic seen through the BMJ's eyes: observations and unanswered questions. | |
Statins for primary prevention: what is the regulator's role? | |
Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. | |
Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence | |
Systematic review of the effects of pertussis vaccines in children. | |
Unintended events following immunization with MMR: a systematic review | |
The use of hepatitis A vaccine in Italy—evidence-based recommendations from an expert panel | |
Vaccines for measles, mumps and rubella in children | |
Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected) | |
Vaccines for preventing influenza in healthy children | |
WHO and pandemic flu. Time for change, WHO | |
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments | |
シナリオで学ぶ医療経済学入門 |